Contributed By Walder Wyss Ltd
Pharmaceutical companies may entrust healthcare professionals with consultancy tasks or services, such as papers and the conduct of meetings; medical or scientific studies; clinical trials; training and participation in consultancy bodies; and provide reasonable compensation for expenditure incurred by them in this connection according to the usual standards.
Such consultancy tasks or services are permitted only if they are agreed upon in writing beforehand, if there is a justified need for them, if the healthcare professional is qualified for them, if not more healthcare professionals are entrusted with them than are needed, if the pharmaceutical companies document them and if the agreements provide that the healthcare professionals will disclose their relationship if they write or speak in public about matters that are the subject of the agreement or otherwise related to the commissioning pharmaceutical company. Sham contracts are prohibited. In addition, pharmaceutical companies must fully disclose all pecuniary benefits and call the attention of the healthcare professional to that obligation in the contracts with them. They must stipulate in the agreement that the recipients of the pecuniary benefits agree to disclosure (rules 21 and 23 et seqq. Pharma Cooperation Code; Guidelines III. 1-7 of the SAMW).